In this article, we will discuss Olaparib (Drug Interactions-1). So, let’s get started.
Anticancer Agents
Clinical studies of Olaparib in combination with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.